Johnson & Johnson

PRECOS appoints Dr. Martin Page scientific consultant

Thursday, March 1, 2012 06:04 AM

Preclinical Oncology Services Limited (PRECOS), a preclinical R&D service provider with a focus on oncology, has appointed Dr. Martin Page scientific consultant.

More... »


J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

More... »


Intellect Neurosciences to appeal in European patent proceedings

Wednesday, February 15, 2012 03:30 PM

Intellect Neurosciences, a biopharmaceutical company focused on disease-modifying therapeutic agents for Alzheimer's disease, submitted a statement setting out its grounds for appealing the European Patent Office's (EPO) preliminary decision to revoke the company's Antisenilin (bapineuzumab) patents.

More... »

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

FDA holds J&J under magnifying glass

Friday, January 13, 2012 01:34 PM

The FDA has trained a watchful eye on Johnson & Johnson as delayed reports, recalls and court trials pile up.

More... »

J&J closes Quebec research center

Wednesday, January 11, 2012 01:12 PM

Johnson & Johnson is closing its Quebec research center, according to a news report on Canada.com.

More... »

Forma and Janssen to collaborate on cancer drug

Wednesday, January 11, 2012 11:19 AM

Forma Therapeutics has formed an exclusive alliance with Janssen Biotech (a subsidiary of Johnson & Johnson), in which the pair will collaborate on discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

More... »

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

More... »

Johnson & Johnson halts Doribax trial due to ‘significant safety concerns’

Monday, January 9, 2012 09:20 AM

Johnson & Johnson shut down a clinical trial of antibiotic Doribax after causing excess mortality and a numerically poorer cure rate than pneumonia subjects treated with imipenem-cilastatin, the generic version of Merck’s Primaxin.

More... »

Janssen, Pharmacyclics collaborate to develop anti-cancer drug

Friday, December 9, 2011 07:56 AM

Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has executed an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765. A number of phase I and II studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs